The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

A new drug approved Thursday by the FDA offers pain management but is not addictive. Unlike opioids, it treats pain signals ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.